178 related articles for article (PubMed ID: 32592633)
21. Randomized Dose-Response Study of the New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension.
Verweij P; Danaietash P; Flamion B; Ménard J; Bellet M
Hypertension; 2020 Apr; 75(4):956-965. PubMed ID: 32063059
[TBL] [Abstract][Full Text] [Related]
22. Assessment of Transporter Polymorphisms as a Factor in a BCRP Drug Interaction Study With Lanabecestat.
Willis BA; Andersen SW; Ayan-Oshodi M; James DE; Liffick E; Hillgren K; Guo Y; Monk SA
J Clin Pharmacol; 2020 Jan; 60(1):107-116. PubMed ID: 31378968
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of rosuvastatin in healthy Chinese volunteers living in China: a randomized, open-label, ascending single- and multiple-dose study.
Li XN; Xu HR; Chen WL; Chu NN; Zhu JR
Clin Ther; 2010 Mar; 32(3):575-87. PubMed ID: 20399994
[TBL] [Abstract][Full Text] [Related]
24. Influence of OATP1B1 and BCRP polymorphisms on the pharmacokinetics and pharmacodynamics of rosuvastatin in elderly and young Korean subjects.
Kim Y; Yoon S; Choi Y; Yoon SH; Cho JY; Jang IJ; Yu KS; Chung JY
Sci Rep; 2019 Dec; 9(1):19410. PubMed ID: 31857620
[TBL] [Abstract][Full Text] [Related]
25. The Effect of BI 730357 (Retinoic Acid-Related Orphan Receptor Gamma t Antagonist, Bevurogant) on the Pharmacokinetics of a Transporter Probe Cocktail, Including Digoxin, Furosemide, Metformin, and Rosuvastatin: An Open-Label, Non-randomized, 2-Period Fixed-Sequence Trial in Healthy Subjects.
Choi H; Huang F; Flack M
Clin Pharmacol Drug Dev; 2024 Feb; 13(2):197-207. PubMed ID: 37960990
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetic interaction between rosuvastatin and olmesartan: a randomized, open-label, 3-period, multiple-dose crossover study in healthy Korean male subjects.
Roh H; Son H; Lee D; Chang H; Yun C; Park K
Clin Ther; 2014 Aug; 36(8):1159-70. PubMed ID: 25017182
[TBL] [Abstract][Full Text] [Related]
27. A pharmacokinetic and pharmacodynamic drug interaction between rosuvastatin and valsartan in healthy subjects.
Jung JA; Lee SY; Kim JR; Ko JW; Jang SB; Nam SY; Huh W
Drug Des Devel Ther; 2015; 9():745-52. PubMed ID: 25767372
[TBL] [Abstract][Full Text] [Related]
28. Evidence for a pharmacokinetic interaction between eslicarbazepine and rosuvastatin: Potential effects on xenobiotic transporters.
Gidal BE; Mintzer S; Schwab M; Schutz R; Kharidia J; Blum D; Grinnell T; Sunkaraneni S
Epilepsy Res; 2017 Sep; 135():64-70. PubMed ID: 28624574
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetic interaction between rosuvastatin and metformin in healthy Korean male volunteers: a randomized, open-label, 3-period, crossover, multiple-dose study.
Lee D; Roh H; Son H; Jang SB; Lee S; Nam SY; Park K
Clin Ther; 2014 Aug; 36(8):1171-81. PubMed ID: 24976448
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of rosuvastatin/olmesartan fixed-dose combination: a single-dose, randomized, open-label, 2-period crossover study in healthy Korean subjects.
Son H; Roh H; Lee D; Chang H; Kim J; Yun C; Park K
Clin Ther; 2013 Jul; 35(7):915-22. PubMed ID: 23810276
[TBL] [Abstract][Full Text] [Related]
31. Pharmacological Characterization of Aprocitentan, a Dual Endothelin Receptor Antagonist, Alone and in Combination with Blockers of the Renin Angiotensin System, in Two Models of Experimental Hypertension.
Trensz F; Bortolamiol C; Kramberg M; Wanner D; Hadana H; Rey M; Strasser DS; Delahaye S; Hess P; Vezzali E; Mentzel U; Ménard J; Clozel M; Iglarz M
J Pharmacol Exp Ther; 2019 Mar; 368(3):462-473. PubMed ID: 30622171
[TBL] [Abstract][Full Text] [Related]
32. Comparison of Pharmacokinetics and Safety of a Fixed-dose Combination of Rosuvastatin and Ezetimibe Versus Separate Tablets in Healthy Subjects.
Min KL; Park MS; Jung J; Chang MJ; Kim CO
Clin Ther; 2017 Sep; 39(9):1799-1810. PubMed ID: 28803122
[TBL] [Abstract][Full Text] [Related]
33. Clinical Drug-Drug Interaction Between Vatiquinone, a 15-Lipoxygenase Inhibitor, and Rosuvastatin, a Breast Cancer Resistance Protein Substrate.
Lee L; Murase K; Ma J; Thoolen M
Clin Pharmacol Drug Dev; 2023 Mar; 12(3):279-286. PubMed ID: 36478438
[TBL] [Abstract][Full Text] [Related]
34. Effect of Daridorexant on the Pharmacokinetics of P-Glycoprotein Substrate Dabigatran Etexilate and Breast Cancer Resistance Protein Substrate Rosuvastatin in Healthy Subjects.
Anliker-Ort M; Dingemanse J; Janů L; Kaufmann P
Clin Drug Investig; 2023 Nov; 43(11):827-837. PubMed ID: 37858005
[TBL] [Abstract][Full Text] [Related]
35. Napabucasin Drug-Drug Interaction Potential, Safety, Tolerability, and Pharmacokinetics Following Oral Dosing in Healthy Adult Volunteers.
Dai X; Karol MD; Hitron M; Hard ML; Goulet MT; McLaughlin CF; Brantley SJ
Clin Pharmacol Drug Dev; 2021 Aug; 10(8):824-839. PubMed ID: 34107166
[TBL] [Abstract][Full Text] [Related]
36. The dual orexin receptor antagonist daridorexant does not affect the pharmacokinetics of the BCRP substrate rosuvastatin.
Zenklusen I; Muehlan C; Ulc I; Liška J; Dingemanse J
Clin Exp Pharmacol Physiol; 2020 Nov; 47(11):1843-1849. PubMed ID: 32603512
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetic interaction between rosuvastatin and telmisartan in healthy Korean male volunteers: a randomized, open-label, two-period, crossover, multiple-dose study.
Son M; Kim Y; Lee D; Roh H; Son H; Guk J; Jang SB; Nam SY; Park K
Clin Ther; 2014 Aug; 36(8):1147-58. PubMed ID: 24998012
[TBL] [Abstract][Full Text] [Related]
38. Effects of Food and Gender on Pharmacokinetics of Rosuvastatin in a Chinese Population Based on 4 Bioequivalence Studies.
Chen J; Lou H; Jiang B; Shao R; Yang D; Hu Y; Xu Y; Ruan Z
Clin Pharmacol Drug Dev; 2020 Feb; 9(2):235-245. PubMed ID: 31148412
[TBL] [Abstract][Full Text] [Related]
39. Effects of Metformin and Furosemide on Rosuvastatin Pharmacokinetics in Healthy Volunteers: Implications for Their Use as Probe Drugs in a Transporter Cocktail.
Stopfer P; Giessmann T; Hohl K; Sharma A; Ishiguro N; Taub ME; Jungnik A; Gansser D; Ebner T; Müller F
Eur J Drug Metab Pharmacokinet; 2018 Feb; 43(1):69-80. PubMed ID: 28685495
[TBL] [Abstract][Full Text] [Related]
40. Effect of enzalutamide on PK of P-gp and BCRP substrates in cancer patients: CYP450 induction may not always predict overall effect on transporters.
Poondru S; Ghicavii V; Khosravan R; Manchandani P; Heo N; Moy S; Wojtkowski T; Patton M; Haas GP
Clin Transl Sci; 2022 May; 15(5):1131-1142. PubMed ID: 35118821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
